Plain-English answer
Chinese healthcare companies entering the United States need more than FDA clearance or a distributor. They need to define the intended use, regulatory pathway, buyer, payer, coding route, coverage evidence, payment economics, hospital purchasing process, liability exposure, service model, privacy obligations, and credibility plan.
When to use this page
Use this FAQ before announcing a U.S. launch, hiring a sales team, signing a distributor, raising capital on a U.S. story, or assuming that FDA clearance creates revenue. The United States is a sequence of gates: regulatory permission, coding, coverage, payment, purchasing, contracting, clinical adoption, service, and risk management.
Fast orientation
U.S. commercialization only works when permission, payment, purchasing, proof, support, and trust are aligned.
Questions and answers
What is the first U.S. question to answer?
Define the product's intended use and claim. For devices, FDA's Device Advice explains that U.S. marketing pathways include 510(k), De Novo, PMA, exempt devices, HDE, and other routes depending on risk and regulatory controls. The intended use drives the evidence and pathway.
Is FDA clearance enough?
No. FDA clearance or approval permits marketing under a defined claim; it does not guarantee Medicare coverage, a CPT or HCPCS code, hospital purchase, physician use, or commercial payer reimbursement.
Do we need a CPT or HCPCS code?
Possibly. CMS maintains guidance for medical technology companies that separates coding, coverage, and payment. A code identifies an item or service for claims; it is not by itself a coverage decision or a payment guarantee.
What evidence do payers want?
Payers often want evidence that the product improves outcomes, reduces avoidable costs, fits a covered benefit, and is reasonable and necessary for the relevant population. Evidence that satisfied FDA may not answer a payer's budget or comparative-effectiveness question.
Should we use a distributor?
Only if the distributor can prove category fit, account access, compliance discipline, service capability, data reporting, and honest economics. A distributor cannot fix an unclear regulatory claim, weak reimbursement logic, or missing service infrastructure.
What makes U.S. hospitals skeptical?
Hospitals may ask whether the product has reimbursement, reduces labor or cost, fits workflow, has reliable service, creates cybersecurity or liability risk, requires new training, or duplicates existing capability. A glossy sales deck rarely answers those questions.
What is different for Chinese companies?
Chinese companies may face extra scrutiny around supply chain, data security, documentation quality, U.S. support, IP, entity structure, and geopolitical perception. FDA's China Office exists partly because China is a major source of FDA-regulated goods for the U.S. market.
Evidence context
Use this FAQ as a readiness checklist. Each question should become a workstream before launch.
- FDA Device Advice explains device marketing pathways and regulatory controls.
- CMS guide for medical technology companies explains coding, coverage, and payment processes.
- FDA China Office explains FDA's on-site China presence and supply-chain role.